MedTrace Logo

Subcutaneous Administration of MD-18 in Healthy Subjects

NCT06259903 · Status: ACTIVE_NOT_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 35

Last updated 2024-10-01

No results posted yet for this study

Summary

A Single Center, Single Dose, Double-blind, Randomized, Placebo-controlled Dose-Escalating Study to Evaluate Safety, Tolerability and Pharmacokinetics of Subcutaneously Administered MD-18 in healthy subjects.

Conditions

  • Healthy Volunteers

Interventions

DRUG

MD-18

Subcutaneous Administration of MD-18 in Healthy Subjects.

Sponsors & Collaborators

  • Cohen Global, Ltd.

    lead INDUSTRY

Principal Investigators

  • Amir Tirosh, Prof · Cohen Global, Ltd.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
SEQUENTIAL

Eligibility

Min Age
18 Years
Max Age
70 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2024-05-07
Primary Completion
2024-12-31
Completion
2025-04-30

Countries

  • Israel

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT06259903 on ClinicalTrials.gov